Event Recap: Hot Topics in Regulatory, Privacy, and Compliance
November 18, 2026Regulatory, compliance, and privacy risks often depend on details that are easy to overlook: how evidence is presented to FDA, why a healthcare professional is paid, or whether a privacy notice matches actual data practices.
In the opening session of our Pharma, Medtech, and Biotech: Regulatory Updates, AI Risks, & Enforcement Trends program, held November 12, 2026, in Newport Beach, California, Nathan Downing, Amanda Johnston, and Paul Rothermel discussed developments affecting FDA engagement, healthcare fraud enforcement, privacy, and AI.
Clear Evidence Supports Better FDA Engagement
Downing discussed how resource constraints and the use of AI in regulatory review can affect companies' interactions with FDA. He emphasized submissions that make the supporting evidence easy to follow, with clear headings, focused explanations, and a direct connection between testing, results, and the question being addressed. Companies should also develop a supported position before asking the agency for feedback.
“So put forth your best answer in your question, but be ready to have some negotiation with FDA.”
Nathan Downing, Managing Attorney
He encouraged early engagement for novel technologies and careful evaluation of new agency programs before making them central to a development plan. Downing also emphasized maintaining a complete record of supporting evidence and agency interactions, particularly when a disagreement may lead to an appeal.
Evaluate Commercial Arrangements in Context
Johnston reviewed healthcare fraud enforcement developments, including coordination among agencies, data analytics, self-disclosure, and whistleblower incentives. She connected those developments with familiar compliance questions involving healthcare professional relationships, promotional activities, and transfers of value.
Her discussion of OIG's guidance highlighted the limits of relying on fair market value alone:
“An arrangement that is consistent with fair market value can still violate the anti-kickback statute.”
Amanda Johnston, Partner
Johnston emphasized the surrounding facts, circumstances, and intentions of the parties. Compensation is one part of that analysis; the purpose and operation of the relationship also matter. She also discussed reassessing reimbursement support programs in light of recent enforcement, with attention to the design and operation of each arrangement.
Privacy Commitments Must Match Actual Practices
Rothermel reviewed the expansion of state privacy requirements, litigation involving website tracking technologies, and governance questions associated with automated decision-making. He also discussed enforcement involving differences between what companies say about personal information and how they actually handle it. His practical emphasis was on ensuring that companies:
“Align what's in the privacy policies and the notices with what's going on in reality.”
Paul Rothermel, Managing Attorney
That point connects public-facing statements with operational questions about data collection, sharing, vendors, and internal controls. The discussion illustrated why privacy review needs input from the teams that select technologies and use data, as well as those responsible for policies and legal review.
Practical Takeaways for FDA-Regulated Companies
The opening briefings identified several priorities for legal, regulatory, compliance, and business teams:
- Prepare FDA submissions that clearly connect testing, results, risk analyses, and the regulatory question being addressed.
- Bring a supported position to agency discussions and preserve the evidence and communications needed to address disagreements.
- Evaluate healthcare professional arrangements in light of their purpose, compensation, and actual operation.
- Reassess reimbursement support programs against relevant enforcement developments and the facts of the arrangement.
- Compare privacy policies and notices with actual data practices, including website tracking and information shared with third parties.
Watch the Discussion and Contact Gardner Law
Watch the session recording above and download the slides for more detail. If your organization is preparing for FDA engagement, reviewing commercial arrangements, or addressing privacy and AI governance, contact Gardner Law for assistance in evaluating the issues and developing a practical approach.